What You Should Know:
– Abbott launches new app, NeuroSphere myPath that will allow patients to record their pain relief during the device trial period with spinal cord stimulation or dorsal root ganglion therapy, simplify reporting outcomes and connect patients to physicians who have real-time access to this data
– NeuroSphere myPath will be available in the Apple App Store in the coming weeks and will be compatible with the latest iOS operating system
Abbott announced the upcoming launch of NeuroSphere™ myPath™, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy. During the device trial period required before the permanent implant, the app allows patients to record their outcomes on pain and well-being while trialing their neurostimulation therapy.
NeuroSphere myPath Background
Abbott’s NeuroSphere myPath is a digital innovation that will provide relief to the millions of Americans currently living with chronic pain that are eligible for SCS or DRG therapy. This new digital health app will allow patients to use their Apple mobile device to connect with Abbott support, access educational resources and track the progress of their trial pain relief journey.
Prior to committing to full implantation of a neuromodulation device, patients undergo a trial period to test device capabilities and capacity for pain relief. During the trial, temporary leads are placed and connected to an external generator, allowing patients to experience firsthand the impact of neuromodulation on their chronic pain and related symptoms.
Why It Matters
Chronic pain can negatively impact personal relationships, work productivity and a person’s daily routine. Abbott is a global leader in the development of chronic pain therapy solutions, offering radiofrequency therapy and spinal cord stimulation therapy solutions, including radiofrequency ablation generators and accessories, BurstDR™ stimulation, and dorsal root ganglion stimulation in the portfolio of chronic pain treatments.
“The current digital healthcare landscape has revolutionized our ability to provide direct care for patients whenever they need,” said Shachi Patel, M.D., interventional pain management physician and owner of Delmarva Pain and Spine Center in Newark, Del. “By providing patients with a more seamless, easier way to record their progress during the trial period, Abbott’s NeuroSphere myPath app will enable an enhanced communication experience while providing patients with further insight on their overall outcomes and response to neuromodulation.”
The NeuroSphere myPath will be available on the Apple App Store in the coming weeks and is expected to be available on Android devices in Q2 2021.